Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 953

1.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.

Ishii H, Azuma K, Sakai K, Naito Y, Matsuo N, Tokito T, Yamada K, Hoshino T, Nishio K.

Sci Rep. 2020 Jan 20;10(1):691. doi: 10.1038/s41598-020-57624-4.

2.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K.

Sci Rep. 2019 Dec 20;9(1):19501. doi: 10.1038/s41598-019-55939-5.

3.

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.

Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, Matsumura N.

Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664-6. doi: 10.1016/j.ygyno.2019.11.013. [Epub ahead of print]

PMID:
31785864
4.

A Preclinical Evaluation towards the Clinical Application of Oxygen Consumption Measurement by CERMs by a Mouse Chimera Model.

Kuno T, Tachibana M, Fujimine-Sato A, Fue M, Higashi K, Takahashi A, Kurosawa H, Nishio K, Shiga N, Watanabe Z, Yaegashi N.

Int J Mol Sci. 2019 Nov 12;20(22). pii: E5650. doi: 10.3390/ijms20225650.

5.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.

Lung Cancer. 2020 Jan;139:28-34. doi: 10.1016/j.lungcan.2019.10.028. Epub 2019 Nov 3.

PMID:
31710890
6.

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K.

J Clin Invest. 2020 Jan 2;130(1):374-388. doi: 10.1172/JCI126598.

7.

Low-Energy-Consumption Three-Valued Memory Device Inspired by Solid-State Batteries.

Watanabe Y, Kobayashi S, Sugiyama I, Nishio K, Liu W, Watanabe S, Shimizu R, Hitosugi T.

ACS Appl Mater Interfaces. 2019 Dec 4;11(48):45150-45154. doi: 10.1021/acsami.9b15366. Epub 2019 Nov 15.

PMID:
31651152
8.

Relationship between the nutritional state of elderly people in need of support or nursing care and jaw-opening force and tongue pressure.

Hoyano K, Tsujihashi E, Nishio K, Tsuji T.

J Phys Ther Sci. 2019 Oct;31(10):747-750. doi: 10.1589/jpts.31.747. Epub 2019 Oct 19.

9.

Association between timing of hot water bathing before bedtime and night-/sleep-time blood pressure and dipping in the elderly: a longitudinal analysis for repeated measurements in home settings.

Tai Y, Saeki K, Yamagami Y, Yoshimoto K, Kurumatani N, Nishio K, Obayashi K.

Chronobiol Int. 2019 Dec;36(12):1714-1722. doi: 10.1080/07420528.2019.1675685. Epub 2019 Oct 15.

PMID:
31610699
10.

Functional regulation of von Willebrand factor ameliorates acute ischemia-reperfusion kidney injury in mice.

Ono S, Matsui H, Noda M, Kasuda S, Yada N, Yoshimoto K, Akiyama M, Miyata T, Sugimoto M, Nishio K.

Sci Rep. 2019 Oct 8;9(1):14453. doi: 10.1038/s41598-019-51013-2.

11.

Vitrification and nanocrystallization of pure liquid Ni studied using molecular-dynamics simulation.

Louzguine-Luzgin DV, Miyama M, Nishio K, Tsarkov AA, Greer AL.

J Chem Phys. 2019 Sep 28;151(12):124502. doi: 10.1063/1.5119307.

PMID:
31575179
12.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.

Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K.

Oncogenesis. 2019 Sep 30;8(10):54. doi: 10.1038/s41389-019-0164-9.

13.

[Current Status and Future Direction of Cancer Genomic Medicine].

Nishio K, Sakai K.

Gan To Kagaku Ryoho. 2019 Sep;46(9):1357-1360. Japanese.

PMID:
31530770
14.

Clinical and immune profiling for cancer of unknown primary site.

Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K.

J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z.

15.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer. 2020 Jan 1;126(1):219-227. doi: 10.1002/cncr.32481. Epub 2019 Sep 10.

PMID:
31503343
16.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, Klein S, Kim Y, MacLeod AR, Sugimoto K, Yoshikawa K, Nishio K, Uemura H.

JCI Insight. 2019 Sep 5;4(17). pii: 122688. doi: 10.1172/jci.insight.122688.

17.

Difficulty classifications of laparoscopic repeated liver resection in patients with recurrent hepatocellular carcinoma.

Kinoshita M, Kanazawa A, Kodai S, Shimizu S, Murata A, Nishio K, Hamano G, Shinkawa H, Tanaka S, Takemura S, Tsukamoto T, Kubo S.

Asian J Endosc Surg. 2019 Aug 13. doi: 10.1111/ases.12746. [Epub ahead of print]

PMID:
31408275
18.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.

Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K.

Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9.

19.

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.

Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M.

Cancer Sci. 2019 Oct;110(10):3350-3357. doi: 10.1111/cas.14153. Epub 2019 Aug 19.

20.

Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed.

Takeda M, Sakai K, Nishio K, Nakagawa K.

Onco Targets Ther. 2019 Jul 8;12:5355-5358. doi: 10.2147/OTT.S211582. eCollection 2019.

21.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.

Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, Nishio K, Ino K.

Sci Rep. 2019 Jul 18;9(1):10426. doi: 10.1038/s41598-019-47030-w.

22.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

Watanabe S, Otani T, Iwasa T, Takahama T, Takeda M, Sakai K, Nishio K, Ito A, Nakagawa K.

Clin Breast Cancer. 2019 Oct;19(5):e589-e592. doi: 10.1016/j.clbc.2019.05.001. Epub 2019 Jun 20. No abstract available.

PMID:
31301988
23.

Reply to A.-M. Conway et al.

Hayashi H, Nishio K, Nakagawa K.

J Clin Oncol. 2019 Aug 10;37(23):2090. doi: 10.1200/JCO.19.00767. Epub 2019 Jun 18. No abstract available.

PMID:
31211602
24.

New Era for Next-Generation Sequencing in Japan.

Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K.

Cancers (Basel). 2019 May 28;11(6). pii: E742. doi: 10.3390/cancers11060742. Review.

25.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T.

Lung Cancer. 2019 Jun;132:59-64. doi: 10.1016/j.lungcan.2019.03.029. Epub 2019 Apr 8.

PMID:
31097095
26.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.

Oncologist. 2019 Aug;24(8):1022-1026. doi: 10.1634/theoncologist.2019-0101. Epub 2019 Apr 25.

27.

Spatiotemporal observations of light propagation in multiple polarization states.

Inoue T, Matsunaka A, Funahashi A, Okuda T, Nishio K, Awatsuji Y.

Opt Lett. 2019 Apr 15;44(8):2069-2072. doi: 10.1364/OL.44.002069.

PMID:
30985813
28.

Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.

Sakai K, Ohira T, Matsubayashi J, Yoneshige A, Ito A, Mitsudomi T, Nagao T, Iwamatsu E, Katayama J, Ikeda N, Nishio K.

Cancer Sci. 2019 Jun;110(6):2044-2049. doi: 10.1111/cas.14016. Epub 2019 May 3.

29.

Entropy-driven docosahedral short-range order in simple liquids and glasses.

Nishio K, Lu AKA, Miyazaki T.

Phys Rev E. 2019 Feb;99(2-1):022121. doi: 10.1103/PhysRevE.99.022121.

PMID:
30934319
30.

Indications for laparoscopic liver resection of mass-forming intrahepatic cholangiocarcinoma.

Kinoshita M, Kanazawa A, Takemura S, Tanaka S, Kodai S, Shinkawa H, Shimizu S, Murata A, Nishio K, Hamano G, Ito T, Tsukamoto T, Kubo S.

Asian J Endosc Surg. 2020 Jan;13(1):46-58. doi: 10.1111/ases.12703. Epub 2019 Mar 28.

PMID:
30924307
31.

Substitutional and interstitial impurity p-type doping of thermoelectric Mg2Si: a theoretical study.

Hirayama N, Iida T, Sakamoto M, Nishio K, Hamada N.

Sci Technol Adv Mater. 2019 Mar 14;20(1):160-172. doi: 10.1080/14686996.2019.1580537. eCollection 2019.

32.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.

Aoyama Y, Sakai K, Kodaka T, Tsunemine H, Nishio K, Itoh T, Inoue D, Takahashi T.

J Clin Exp Hematop. 2019 Mar 27;59(1):29-33. doi: 10.3960/jslrt.18037. Epub 2019 Feb 7.

33.

RASGRP2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells.

Sato T, Takino JI, Nagamine K, Nishio K, Hori T.

ScientificWorldJournal. 2019 Jan 1;2019:4639165. doi: 10.1155/2019/4639165. eCollection 2019.

34.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K.

J Clin Oncol. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771. Epub 2019 Jan 17.

PMID:
30653423
35.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K.

Lung Cancer. 2019 Jan;127:59-65. doi: 10.1016/j.lungcan.2018.11.025. Epub 2018 Nov 23.

PMID:
30642552
36.

HOXA10 expression profiling in prostate cancer.

Hatanaka Y, de Velasco MA, Oki T, Shimizu N, Nozawa M, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

Prostate. 2019 Apr;79(5):554-563. doi: 10.1002/pros.23761. Epub 2019 Jan 6.

PMID:
30614022
37.

Evolution of Reactions of a Fluoride Shuttle Battery at the Surfaces of BiF3 Microclusters Studied by In Situ Raman Microscopy.

Yamanaka T, Okazaki KI, Abe T, Nishio K, Ogumi Z.

ChemSusChem. 2019 Jan 24;12(2):527-534. doi: 10.1002/cssc.201802209. Epub 2019 Jan 2.

PMID:
30450797
38.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13.

39.

A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.

Iwahashi N, Sakai K, Noguchi T, Yahata T, Toujima S, Nishio K, Ino K.

Oncol Lett. 2018 Nov;16(5):6431-6436. doi: 10.3892/ol.2018.9467. Epub 2018 Sep 20.

40.

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.

Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.

Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.

41.

Extending recordable time of light-in-flight recording by holography with double reference light pulses.

Sawashima Y, Yamanaka D, Takamoto I, Matsunaka A, Awatsuji Y, Nishio K.

Opt Lett. 2018 Oct 15;43(20):5146-5149. doi: 10.1364/OL.43.005146.

PMID:
30320841
42.

Serpina3n, Dominantly Expressed in Female Osteoblasts, Suppresses the Phenotypes of Differentiated Osteoblasts in Mice.

Ishida M, Kawao N, Okada K, Tatsumi K, Sakai K, Nishio K, Kaji H.

Endocrinology. 2018 Nov 1;159(11):3775-3790. doi: 10.1210/en.2018-00639.

PMID:
30304388
43.

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.

Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9.

PMID:
30302022
44.

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer Sci. 2018 Dec;109(12):3921-3933. doi: 10.1111/cas.13820. Epub 2018 Nov 13.

45.

Structure of glyoxysomal malate dehydrogenase (MDH3) from Saccharomyces cerevisiae.

Moriyama S, Nishio K, Mizushima T.

Acta Crystallogr F Struct Biol Commun. 2018 Oct 1;74(Pt 10):617-624. doi: 10.1107/S2053230X18011895. Epub 2018 Sep 19.

PMID:
30279312
46.

Acid-electrolyzed functional water induces extracellular matrix metalloproteinase inducer, a possible novel alarmin, secretion from oral squamous cell carcinoma cell lines.

Kusunoki M, Sata E, Nishio K, Tanaka T, Nishida T, Sugano N, Sato S, Asano M.

Int J Med Sci. 2018 Sep 7;15(12):1365-1372. doi: 10.7150/ijms.26186. eCollection 2018.

47.

Low-Temperature Spark Plasma Sintering of ZrW2-xMoxO₈ Exhibiting Controllable Negative Thermal Expansion.

Wei H, Hasegawa M, Mizutani S, Aimi A, Fujimoto K, Nishio K.

Materials (Basel). 2018 Sep 1;11(9). pii: E1582. doi: 10.3390/ma11091582.

48.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

49.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

50.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312. No abstract available.

Supplemental Content

Loading ...
Support Center